. 2023 Nov 24;12(2):101726. doi: 10.1016/j.jvsv.2023.101726

Table III.

The pooled event rate per 100 patient-years of venous thromboembolism (VTE) and bleeding according to the duration of anticoagulation treatment

Duration of anticoagulation	VTE	SVT progression or recurrence	DVT	PE	Major bleeding	CRNM and minor bleeding
All studies	27.8 (21.4-34.9)	23.3 (15.8-35.8)	7.9 (5.4-10.9)	1.3 (0.8-2.0)	0.3 (0.2-0.6)^a	7.4 (4.0-11.7)
0 days	28.8 (12.0-52.4)	61.5 (11.5-147.6)	8.3 (2.4-17.5)	1.9 (0.8-3.7)^a	0.5 (0.1-1.4)^a	4.8 (2.8-7.4)^a
≤14 days	59.7 (37.7-86.4)	41.3 (17.9-73.9)	13.7 (9.6-18.4)^a	3.1 (1.4-5.6)^a	0.5 (0.0-2.7)^a	1.4 (0.1-4.3)^a
15-30 days	25.4 (16.3-36.6)	18.8 (9.7-30.9)	5.5 (2.8-9.1)	0.9 (0.5-1.3)^a	0.3 (0.1-0.6)^a	5.8 (1.6-12.6)
31-45 days	16.2 (10.4-23.3)	8.2 (3.1-15.8)	7.8 (3.0-14.9)	1.4 (0.2-3.8)	0.3 (0.1-0.7)^a	14.2 (5.5-26.8)

CRNM, Clinically relevant non-major; DVT, deep vein thrombosis; PE, pulmonary embolism; SVT, superficial vein thrombosis.

Indicates low heterogeneity (P > .05 and I²< 50%).